Advanced Oncotherapy (AVO) – Total Voting Rights

Further to the announcement of 7 November 2016, Advanced Oncotherapy (AIM: AVO), the developer of next-generation proton therapy systems for cancer treatment, announces that due to a clerical error, 24,505 new ordinary shares of 25 pence each in the Company were not issued and allotted of the 266,668 new Ordinary Shares to be issued as […]

Advanced Oncotherapy (AVO) – Additional director dealing

Advanced Oncotherapy (AIM: AVO), the developer of next-generation proton therapy systems for cancer treatment, announces that further to the notification earlier today Dr Enrico Vanni, Non-Executive Director, has today purchased a further 25,000 ordinary shares of 25 pence in the Company at a price of 29.25 pence per Ordinary Share.  Following this transaction, Dr Vanni […]

Advanced Oncotherapy (AVO) – Director Dealing

Advanced Oncotherapy (AIM: AVO), the developer of next-generation proton therapy systems for cancer treatment, announces that yesterday the Directors below purchased ordinary shares of 25 pence in the Company. Director No of Ordinary Shares purchased   Price paid Resultant shareholding   %  of the issued share capital Dr Michael Sinclair, Executive Chairman 100,000 28.35p 4,728,229 6.51% Dr […]

Advanced Oncotherapy (AVO) – Result of General Meeting

Advanced Oncotherapy plc (AIM: AVO), the developer of next generation proton therapy systems for cancer treatment, announces that at the General Meeting held earlier today all resolutions were passed.download full film iBoy As a result the Board now has authority to utilise the Equity Financing Facility provided by Bracknor, details of which were provided in […]

Advanced Oncotherapy (AVO) – Additional financing agreement

Advanced Oncotherapy plc (AIM: AVO), the developer of next generation proton therapy systems for cancer treatment, announces that on Friday 24 March it signed an additional 12-month convertible and redeemable loan, at a conversion price of 100p, which will provide net funding of £3m, with an option to draw-down a further £2m within the next […]

Asia Cancer Market Update – MedTech Intelligence

Asia Cancer Market Update by Ames Gross Government healthcare expenditures in Asian countries has been increasing steadily in recent years. According to a 2016 Deloitte report, the average annual increase in government healthcare spending in Asian countries is more than 6%, compared to 4.5% in the United States and less than 1.5% in the European […]

Advanced Oncotherapy (AVO) – Major Shareholder increases stake

NOTIFICATION OF MAJOR INTEREST IN SHARES  download movie War for the Planet of the Apes 2017 1. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached: ii Advanced Oncotherapy plc   2 Reason for the notification (please tick the appropriate box or boxes): An acquisition or disposal […]

Advanced Oncotherapy (AVO) – Hardman Research: Delivery of LIGHT

Delivery of LIGHT: AVO is focused on delivering a more affordable, novel, proton-based radiotherapy system, based on technology originally developed at the world renowned CERN. The company is entering an exciting stage with construction work on its Harley Street site expected to commence this month following preliminary assessment work. Meanwhile, individual modules for the LIGHT […]